<DOC>
	<DOC>NCT01479595</DOC>
	<brief_summary>This study is designed to investigate the efficacy and safety of QBX258 in subjects with moderate to severe asthma.</brief_summary>
	<brief_title>A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Patients with atopic asthma &gt;1 year duration diagnosed according to the GINA guidelines. Subjects must weigh at least 50 kg to participate in the study, and must have a body mass index (BMI) within the range of 18 39 kg/m2. Asthma which is not adequately controlled on current treatment, as demonstrated by an Asthma Control Questionnaire (ACQ) score of &gt; 1.5. FEV1 40 to 90% of predicted. Diagnosed with COPD as defined by the GOLD guidelines Subjects who have had a respiratory tract infection within 4 weeks prior to screening. Women of childbearing potential must use highly effective methods of contraception during dosing and for at least 18 weeks after last study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Interleukin</keyword>
	<keyword>QBX258</keyword>
	<keyword>QAX576</keyword>
	<keyword>VAK694</keyword>
</DOC>